Loading...
JW (Cayman) Therapeutics Co. Ltd
JWCTF•PNK
Healthcare
Biotechnology
$0.25
$0.00(0.00%)
JW (Cayman) Therapeutics Co. Ltd (JWCTF) Financial Performance & Income Statement Overview
Review JW (Cayman) Therapeutics Co. Ltd’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-8.99%
↓ 8.99%
Operating Income Growth
41.83%
↑ 41.83%
Net Income Growth
23.10%
↑ 23.10%
Operating Cash Flow Growth
100.00%
↑ 100.00%
Operating Margin
-374.25%
↓ 374.25%
Gross Margin
50.40%
↑ 50.40%
Net Profit Margin
-363.06%
↓ 363.06%
ROE
-47.36%
↓ 47.36%
ROIC
-53.25%
↓ 53.25%
JW (Cayman) Therapeutics Co. Ltd (JWCTF) Income Statement & Financial Overview
Review JW (Cayman) Therapeutics Co. Ltd's (JWCTF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $71.40M | $86.81M | $86.12M | $87.74M |
| Cost of Revenue | $37.83M | $43.07M | $42.71M | $42.93M |
| Gross Profit | $33.57M | $43.74M | $43.41M | $44.81M |
| Gross Profit Ratio | $0.47 | $0.50 | $0.50 | $0.51 |
| R&D Expenses | $131.98M | $151.008M | $197.09M | $216.53M |
| SG&A Expenses | $125.08M | $135.41M | $114.38M | $138.86M |
| Operating Expenses | -$213.94M | $291.26M | $443.09M | $434.73M |
| Total Costs & Expenses | -$176.11M | $334.33M | $485.80M | $477.66M |
| Interest Income | $0.00 | $0.00 | $12.11M | $9.51M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $41.86M | $35.59M | $36.14M | $41.32M |
| EBITDA | -$176.66M | -$204.92M | -$225.48M | -$267.21M |
| EBITDA Ratio | -$2.47 | -$2.36 | -$2.62 | -$3.05 |
| Operating Income | $247.51M | -$247.51M | -$399.69M | -$308.53M |
| Operating Income Ratio | $3.47 | -$2.85 | -$4.64 | -$3.52 |
| Other Income/Expenses (Net) | -$597.87M | $7.25M | $12.11M | -$71.88M |
| Income Before Tax | -$350.36M | -$240.27M | -$387.58M | -$380.42M |
| Income Before Tax Ratio | -$4.91 | -$2.77 | -$4.50 | -$4.34 |
| Income Tax Expense | $0.00 | $0.00 | $138.07M | $0.00 |
| Net Income | -$350.36M | -$240.27M | -$387.58M | -$380.42M |
| Net Income Ratio | -$4.91 | -$2.77 | -$4.50 | -$4.34 |
| EPS | -$0.85 | -$0.58 | -$0.94 | -$0.93 |
| Diluted EPS | -$0.85 | -$0.58 | -$0.94 | -$0.93 |
| Weighted Avg Shares Outstanding | $414.19M | $413.08M | $411.93M | $411.13M |
| Weighted Avg Shares Outstanding (Diluted) | $414.19M | $413.08M | $411.93M | $411.13M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan